{"transactions":[{"id":724094,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-29T23:03:15.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":29888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date."}],"balance_after":29888,"derivative":{"exercise_price":16.01,"exercise_date":"2027-06-26","expiration_date":"2036-06-26","underlying":"Common Stock","underlying_shares":29888},"source":{"system":"sec-edgar","filing":"0001193125-26-288903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526288903/ownership.xml","form_type":"4"}},{"id":1066415,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T20:52:50.000Z","date":"2025-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the \"Company\"), Concentra Biosciences, LLC, a Delaware limited liability company (\"Parent\"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), on August 14, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a \"CVR\") subject to the terms and conditions of a Contingent Value Rights Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the \"Company\"), Concentra Biosciences, LLC, a Delaware limited liability company (\"Parent\"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), on August 14, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a \"CVR\") subject to the terms and conditions of a Contingent Value Rights Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-022042","document":"form4-08152025_120847.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000141588925022042/form4-08152025_120847.xml","form_type":"4"}},{"id":1094282,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:24:48.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":44.77,"underlying":"Common Stock","underlying_shares":12216},"source":{"system":"sec-edgar","filing":"0001104659-25-065315","document":"tm2519678-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925065315/tm2519678-12_4seq1.xml","form_type":"4"}},{"id":1094281,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:24:48.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15318,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":35.42,"underlying":"Common Stock","underlying_shares":15318},"source":{"system":"sec-edgar","filing":"0001104659-25-065315","document":"tm2519678-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925065315/tm2519678-12_4seq1.xml","form_type":"4"}},{"id":1094280,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:24:48.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14668,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":38.03,"underlying":"Common Stock","underlying_shares":14668},"source":{"system":"sec-edgar","filing":"0001104659-25-065315","document":"tm2519678-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925065315/tm2519678-12_4seq1.xml","form_type":"4"}},{"id":1094279,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T20:24:48.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14155,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 10,060 shares underlying restricted stock units (each, an \"RSU\") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a \"Parent Cash-Based RSU Award\"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065315","document":"tm2519678-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925065315/tm2519678-12_4seq1.xml","form_type":"4"}},{"id":1101092,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-26T20:27:06.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date."}],"balance_after":120000,"derivative":{"exercise_price":1.45,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-25-090423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017025090423/ownership.xml","form_type":"4"}},{"id":1146985,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T22:44:25.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":10060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 14, 2026 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":14155,"source":{"system":"sec-edgar","filing":"0001104659-25-049659","document":"tm2515271-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925049659/tm2515271-4_4seq1.xml","form_type":"4"}},{"id":1271114,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T00:57:25.000Z","date":"2025-02-10","kind":"exercise","planned":true,"acquired":false,"shares":13774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":32.27,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":13774},"source":{"system":"sec-edgar","filing":"0001104659-25-012362","document":"tm256428-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925012362/tm256428-2_4seq1.xml","form_type":"4"}},{"id":1271113,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-13T00:57:25.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":13774,"price":53.0134,"value":730206.5716,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":4095,"source":{"system":"sec-edgar","filing":"0001104659-25-012362","document":"tm256428-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925012362/tm256428-2_4seq1.xml","form_type":"4"}},{"id":1271112,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-13T00:57:25.000Z","date":"2025-02-10","kind":"exercise","planned":true,"acquired":true,"shares":13774,"price":32.27,"value":444486.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."}],"balance_after":17869,"source":{"system":"sec-edgar","filing":"0001104659-25-012362","document":"tm256428-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465925012362/tm256428-2_4seq1.xml","form_type":"4"}},{"id":1447135,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-29T17:45:15.000Z","date":"2024-07-25","kind":"exercise","planned":true,"acquired":false,"shares":15132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":1.39,"expiration_date":"2028-12-22","underlying":"Common Stock","underlying_shares":15132},"source":{"system":"sec-edgar","filing":"0001415889-24-020266","document":"form4-07292024_090711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000141588924020266/form4-07292024_090711.xml","form_type":"4"}},{"id":1447134,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-29T17:45:15.000Z","date":"2024-07-25","kind":"sale","planned":true,"acquired":false,"shares":15132,"price":14,"value":211848.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001415889-24-020266","document":"form4-07292024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000141588924020266/form4-07292024_090711.xml","form_type":"4"}},{"id":1447133,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-29T17:45:15.000Z","date":"2024-07-25","kind":"exercise","planned":true,"acquired":true,"shares":15132,"price":1.39,"value":21033.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024."}],"balance_after":17132,"source":{"system":"sec-edgar","filing":"0001415889-24-020266","document":"form4-07292024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000141588924020266/form4-07292024_090711.xml","form_type":"4"}},{"id":1472131,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T12:44:14.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options to purchase shares vest on June 20, 2025, subject to the Reporting Person's continuous service to the Issuer on such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":2.03,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-24-005922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919124005922/doc4.xml","form_type":"4"}},{"id":1489475,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:08:06.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":20,"price":42.0905,"value":841.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $42.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":4095,"source":{"system":"sec-edgar","filing":"0001104659-24-068674","document":"tm2416457-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465924068674/tm2416457-2_4seq1.xml","form_type":"4"}},{"id":1489474,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:08:06.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":931,"price":41.4924,"value":38629.4244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.02 to $42.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":4115,"source":{"system":"sec-edgar","filing":"0001104659-24-068674","document":"tm2416457-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465924068674/tm2416457-2_4seq1.xml","form_type":"4"}},{"id":1489473,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:08:06.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":751,"price":40.5665,"value":30465.4415,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":5046,"source":{"system":"sec-edgar","filing":"0001104659-24-068674","document":"tm2416457-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465924068674/tm2416457-2_4seq1.xml","form_type":"4"}},{"id":1489472,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:08:06.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":2946,"price":39.4132,"value":116111.2872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":5797,"source":{"system":"sec-edgar","filing":"0001104659-24-068674","document":"tm2416457-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465924068674/tm2416457-2_4seq1.xml","form_type":"4"}},{"id":1510571,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:04:13.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":12216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in full on the earlier of (i) May 16, 2025 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":12216,"derivative":{"exercise_price":44.77,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":12216},"source":{"system":"sec-edgar","filing":"0001104659-24-062979","document":"tm2414847-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465924062979/tm2414847-3_4seq1.xml","form_type":"4"}},{"id":1510570,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-17T20:04:13.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":4095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 16, 2025 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":8743,"source":{"system":"sec-edgar","filing":"0001104659-24-062979","document":"tm2414847-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465924062979/tm2414847-3_4seq1.xml","form_type":"4"}},{"id":1576652,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-14T17:54:22.000Z","date":"2024-03-12","kind":"grant","planned":false,"acquired":true,"shares":29400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the shares subject to the option shall vest each month following the Issuer's 2024 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2025 Annual Meeting of Stockholders."}],"balance_after":29400,"derivative":{"exercise_price":9.95,"expiration_date":"2034-03-12","underlying":"Common Stock","underlying_shares":29400},"source":{"system":"sec-edgar","filing":"0001415889-24-008029","document":"form4-03142024_090316.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000141588924008029/form4-03142024_090316.xml","form_type":"4"}},{"id":1824666,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-21T20:13:38.000Z","date":"2023-07-19","kind":"sale","planned":true,"acquired":false,"shares":2418,"price":29.3118,"value":70875.9324,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.94 to $29.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":4648,"source":{"system":"sec-edgar","filing":"0001104659-23-083048","document":"tm2321735-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465923083048/tm2321735-1_4seq1.xml","form_type":"4"}},{"id":1844261,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T13:10:41.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options to purchase shares vest on June 22, 2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":2.66,"exercise_date":"2024-06-22","expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-23-039584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919123039584/doc4.xml","form_type":"4"}},{"id":1846181,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:06:40.000Z","date":"2023-06-20","kind":"sale","planned":true,"acquired":false,"shares":2400,"price":26.918,"value":64603.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.44 to $27.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":7066,"source":{"system":"sec-edgar","filing":"0001104659-23-073743","document":"tm2319378-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465923073743/tm2319378-1_4seq1.xml","form_type":"4"}},{"id":1877693,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:26:55.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":13774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":13774,"derivative":{"exercise_price":32.27,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":13774},"source":{"system":"sec-edgar","filing":"0001104659-23-064646","document":"tm2317015-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465923064646/tm2317015-3_4seq1.xml","form_type":"4"}},{"id":1877692,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T20:26:55.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":4648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":9466,"source":{"system":"sec-edgar","filing":"0001104659-23-064646","document":"tm2317015-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465923064646/tm2317015-3_4seq1.xml","form_type":"4"}},{"id":1923712,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-06T21:39:59.000Z","date":"2023-04-04","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the shares subject to the option shall vest each month following the Issuer's 2023 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":15500,"derivative":{"exercise_price":12.86,"expiration_date":"2033-04-04","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-23-023697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919123023697/doc4.xml","form_type":"4"}},{"id":1949644,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-16T20:31:34.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":1106,"price":31.5021,"value":34841.3226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.5004 to $31.5200. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":4818,"source":{"system":"sec-edgar","filing":"0001104659-23-033345","document":"tm239766-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465923033345/tm239766-1_4seq1.xml","form_type":"4"}},{"id":2222125,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T13:17:11.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.35,"exercise_date":"2023-06-22","expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-039103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919122039103/doc4.xml","form_type":"4"}},{"id":2261439,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T21:40:55.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":15318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":15318,"derivative":{"exercise_price":35.42,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":15318},"source":{"system":"sec-edgar","filing":"0001104659-22-063506","document":"tm2216253-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465922063506/tm2216253-2_4seq1.xml","form_type":"4"}},{"id":2261438,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-20T21:40:55.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":4818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4 filed on May 21, 2021."}],"balance_after":5924,"source":{"system":"sec-edgar","filing":"0001104659-22-063506","document":"tm2216253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465922063506/tm2216253-2_4seq1.xml","form_type":"4"}},{"id":2333198,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-15T20:56:29.000Z","date":"2022-03-12","kind":"grant","acquired":true,"shares":29497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the shares subject to the option shall vest each month following the Issuer's 2022 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":29497,"derivative":{"exercise_price":17.11,"expiration_date":"2032-03-12","underlying":"Common Stock","underlying_shares":29497},"source":{"system":"sec-edgar","filing":"0001209191-22-019016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919122019016/doc4.xml","form_type":"4"}},{"id":2606820,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-11T21:37:10.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":1000,"price":80,"value":80000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-21-051011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919121051011/doc4.xml","form_type":"4"}},{"id":2629305,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-21T00:43:06.000Z","date":"2021-07-20","kind":"purchase","acquired":true,"shares":6000,"price":16,"value":96000.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000899243-21-029053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000089924321029053/doc4.xml","form_type":"4"}},{"id":2683217,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T20:29:28.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":2000,"price":80,"value":160000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-21-038002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919121038002/doc4.xml","form_type":"4"}},{"id":2700327,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-21T20:32:28.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":6998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date."}],"balance_after":6998,"derivative":{"exercise_price":75.94,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":6998},"source":{"system":"sec-edgar","filing":"0001104659-21-070518","document":"tm2117215-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465921070518/tm2117215-4_4seq1.xml","form_type":"4"}},{"id":2700326,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-21T20:32:28.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards. The restricted stock awards shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date."}],"balance_after":5995,"source":{"system":"sec-edgar","filing":"0001104659-21-070518","document":"tm2117215-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465921070518/tm2117215-4_4seq1.xml","form_type":"4"}},{"id":2839276,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-23T21:30:53.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":6423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the shares subject to the option shall vest each month following the Issuer's 2021 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2022 Annual Meeting of Stockholders."}],"balance_after":6423,"derivative":{"exercise_price":91.5,"expiration_date":"2031-02-19","underlying":"Common Stock","underlying_shares":6423},"source":{"system":"sec-edgar","filing":"0001209191-21-013587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919121013587/doc4.xml","form_type":"4"}},{"id":3136561,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:34:51.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":14668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 12 equal quarterly installments following May 20, 2020, subject to continued service to the Issuer on each vesting date."}],"balance_after":14668,"derivative":{"exercise_price":38.03,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":14668},"source":{"system":"sec-edgar","filing":"0001104659-20-065405","document":"tm2020645d2_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000110465920065405/tm2020645d2_form4.xml","form_type":"4"}},{"id":3248302,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-25T21:02:06.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":62500,"derivative":{"exercise_price":6.92,"expiration_date":"2030-02-20","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001567619-20-004800","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578771/000156761920004800/doc1.xml","form_type":"4"}},{"id":3284482,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-02-07T17:45:04.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the shares subject to the option shall vest each month following the Issuer's 2020 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2021 Annual Meeting of Stockholders."}],"balance_after":10000,"derivative":{"exercise_price":40.27,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-007610","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919120007610/doc4.xml","form_type":"4"}},{"id":3408958,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T21:10:43.000Z","date":"2019-09-18","kind":"purchase","acquired":true,"shares":5000,"price":18.31,"value":91550.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-050410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919119050410/doc4.xml","form_type":"4"}},{"id":3409869,"issuer":{"id":76422,"kind":"organization","name":"IGM Biosciences, Inc.","symbol":"IGMS"},"owners":[{"id":34830,"kind":"person","name":"Hambleton Julie","position":1,"cik":"0001578771","reported_name":"Hambleton Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-09-19T21:25:05.000Z","date":"2019-09-17","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the option shall vest on September 17, 2020 and an additional 1/36 of the shares subject to the option shall vest monthly thereafter subject to Reporting Person remaining a service provider through each such date."}],"balance_after":12100,"derivative":{"exercise_price":16,"expiration_date":"2029-09-17","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001209191-19-050254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496323/000120919119050254/doc4.xml","form_type":"4"}}]}